Chronic Kidney Disease

Welcome and introduction, presentation 1 and case presentation

Welcome & introduction presentation slides, Ioannis Parodis presentation slides, Liz Lightstone & Iaonnis Parodis presentation slide.

IMAGINATION: A Global Phase 3 Trial of RO7434656, an Antisense Oligonucleotide Inhibitor of Complement Factor B, in IgA Nephropathy

The aim of the IMAGINATION trial is to evaluate the efficacy, safety and pharmacokinetics of RO7434656 compared with placebo in adults with biopsy-confirmed primary IgA nephropathy (IgAN).

Longitudinal Assessment of Biomarkers in NOBILITY, a Randomized, Phase II Clinical Trial of Obinutuzumab for Treatment of Proliferative Lupus Nephritis

This post-hoc analyses evaluated changes in peripheral B cells, B-cell subsets and serum biomarkers of disease activity (autoantibodies, complement C3/C4) in patients with lupus nephritis treated with obinutuzumab in the Phase II, randomized, double-blind, placebo-controlled NOBILITY trial (NCT02550652).

IMAGINATION: A Global Phase 3 Trial of RO7434656, an Antisense Oligonucleotide Inhibitor of Complement Factor B, in IgA Nephropathy

The aim of the IMAGINATION trial is to evaluate the efficacy, safety and pharmacokinetics of RO7434656 compared with placebo in adults with biopsy-confirmed primary IgA nephropathy (IgAN).

Validating modelling-based predictions of continuous erythropoietin receptor activator (C.E.R.A.) using real-world and clinical trial data of pediatric patients with chronic kidney disease (CKD): updated analysis from the IPDN registries

This poster compares real-world and clinical trial data from paediatric patients on C.E.R.A. with simulations from a population pharmacokinetic/ pharmacodynamic model to further validate the predictive performance of the model.

External site

Chronic Kidney Disease

Ask a question or share feedback